Erratum to: “Lower incidence of chronic graft-versus-host disease after ruxolitinib plus extracorporeal photopheresis versus ruxolitinib alone in steroid-refractory acute graft-versus-host disease following allogeneic stem cell transplantation”

We have observed some errors in the recently published manuscript “Lower incidence of chronic graft-versus-host disease after ruxolitinib plus extracorporeal photopheresis versus ruxolitinib alone in steroid-refractory acute graft-versus-host disease following allogeneic stem cell transplantationm”.¹

The correct cumulative incidence of chronic graft-versus-host disease (cGvHD) and the 95% Confidence Interval (95%CI) in the Abstract need to be corrected in the Results section and in Table 4A.

1. • In the Abstract, the 1-year cumulative incidence of cGvHD is correct as:
2. Ruxolitinib: 49% (95%CI: 33-69%)
3. Ruxolitinib + ECP: 24% (95%CI: 15-38%)
4. • In the Results section, it is:
5. Ruxolitinib: 41% (95%CI: 31-67%); this should be corrected to 49% (95%CI: 33-69%)
6. Ruxolitinib + ECP: 24% (95%CI: 14-27%); this should be corrected to 24% (CI: 15-38%)
7. • In Table 4A, the 1-year cumulative incidence of cGvHD is: Ruxolitinib: 51 (33-69); this should be corrected to 49 (33-69)
8. Ruxolitinib + ECP: 25% (95%CI: 15-38%); this should be corrected to 24 (15-38).

Correct sentence of the Results section and the correct Table are shown below.

Chronic graft-versus-host disease, and chronic graft-versus-host disease, relapse-free survival and failure-free survival

At six and 12 months, 25% and 20% of evaluable patients in the Ruxo-ECP cohort and 20% and 66% of evaluable patients in the Ruxo cohort experienced cGvHD, resulting in a cumulative incidence of cGvHD at one year of 24% (95%CI: 15-38%) after Ruxo-ECP and 49% (95%CI: 33-69%) after Ruxo.

Correct Table 4.Outcome of steroid-refractory-acute graft-versus-host disease.

Footnotes

• Received November 3, 2025
• Accepted November 3, 2025

Correspondence

N. Kröger nmkroeger@outlook.de